TriSalus Life Sciences, Inc. Warrant
TLSIW
About: TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Employees: 110
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
12% more capital invested
Capital invested by funds: $1.11M [Q1] → $1.25M (+$135K) [Q2]
0.06% less ownership
Funds ownership: 3.01% [Q1] → 2.95% (-0.06%) [Q2]
17% less funds holding
Funds holding: 6 [Q1] → 5 (-1) [Q2]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Financial journalist opinion
We haven’t received any recent news articles for TLSIW